Ignite Creation Date:
2024-10-25 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503952
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
Impact of Uterine Immune Profiling and Personalized Treatments in Patients Receiving a Single Blastocyst a Matched Controlled Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Impact of Uterine Immune Profiling and Personalized Treatments on Subsequent Live Birth in Patients Receiving a Single Blastocyst a Matched Controlled Study
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
UTIMPROSET
Brief Summary:
Previous Randomised controlled study and cohort studies suggested that personalization of care based on the uterine immune profiling performed before an embryo transfer increase subsequent Live birth rate The weakness of previous studies relies on the fact that the transfer policy applied had some possibly impact on the subsequent live birth rate observed Indeed it is well known that day-3 and Day-5 embryos do not have the same implantation rate and that the number of embryos transferred may also impact the subsequent live birth rate
To complete previous studies the present study aims to select a population who had an uterine immune profiling between January 1st 2020 and June 30th 2023 and an single Day-5 fresh or freeze-thawed embryo transfer SET within the next nine months following the uterine immune profiling This population will be matched on age number of previous embryo transfer and type of transfer fresh of freeze-thawed to a population who did not had any uterine immune profiling the nine months before the single Day-5 embryo transfer The outcome is the subsequent Live birth rate following the Day-5 SET among the population who benefitted of an immune profiling before SET and the control population who did not benefited of a uterine immune profile before SET
To complete previous studies the present study aims to select a population who had an uterine immune profiling between January 1st 2020 and June 30th 2023 and an single Day-5 fresh or freeze-thawed embryo transfer SET within the next nine months following the uterine immune profiling This population will be matched on age number of previous embryo transfer and type of transfer fresh of freeze-thawed to a population who did not had any uterine immune profiling the nine months before the single Day-5 embryo transfer The outcome is the subsequent Live birth rate following the Day-5 SET among the population who benefitted of an immune profiling before SET and the control population who did not benefited of a uterine immune profile before SET
Detailed Description:
All the uterine immune profiles performed during January 2020 and June 2023 for patients involved in the two reproductive centre of Bluets and Diaconnesse are extracted from the PRECONCEPTIO software In parallel extraction of data from the medifirst software select all the patients who benefitted of a Day-5 single embryo transfer from Juanary 2020 to march 2024 is compiled The treated group represents the selection of patients who had both an uterine immune profiling before ET and a single Day-5 embryo transfer within the nine months following the uterine immune profiling Each patients of the treated group will be matched to patients who benefitted of a single Day-5 ET without any immune profiling the nine months before ET Matching criteria are the maternal age the number of previous oocytes pickup the number of previous ET and the technique applied IVF ICSI freeze embryo transfer LBR are compared between the treated group with uterine Immune profiling and the control group who receive conventional standard treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None